Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Corine E. Delsing is active.

Publication


Featured researches published by Corine E. Delsing.


Journal of Infection | 2012

Chronic Q fever: review of the literature and a proposal of new diagnostic criteria.

M. C. A. Wegdam-Blans; Linda M. Kampschreur; Corine E. Delsing; Chantal P. Bleeker-Rovers; Tom Sprong; M.E.E. van Kasteren; D.W. Notermans; Nicole H. M. Renders; H.A. Bijlmer; Peter J. Lestrade; M.P.G. Koopmans; Marrigje H. Nabuurs-Franssen; Jan Jelrik Oosterheert

A review was performed to determine clinical aspects and diagnostic tools for chronic Q fever. We present a Dutch guideline based on literature and clinical experience with chronic Q fever patients in The Netherlands so far. In this guideline diagnosis is categorized as proven, possible or probable chronic infection based on serology, PCR, clinical symptoms, risk factors and diagnostic imaging.


Journal of Clinical Microbiology | 2014

Chronic Q Fever in the Netherlands 5 Years after the Start of the Q Fever Epidemic: Results from the Dutch Chronic Q Fever Database

Linda M. Kampschreur; Corine E. Delsing; Rolf H.H. Groenwold; M. C. A. Wegdam-Blans; Chantal P. Bleeker-Rovers; M. G. L. de Jager-Leclercq; Andy I. M. Hoepelman; M.E.E. van Kasteren; J. Buijs; Nicole H. M. Renders; Marrigje H. Nabuurs-Franssen; Jan Jelrik Oosterheert; Peter C. Wever

ABSTRACT Coxiella burnetii causes Q fever, a zoonosis, which has acute and chronic manifestations. From 2007 to 2010, the Netherlands experienced a large Q fever outbreak, which has offered a unique opportunity to analyze chronic Q fever cases. In an observational cohort study, baseline characteristics and clinical characteristics, as well as mortality, of patients with proven, probable, or possible chronic Q fever in the Netherlands, were analyzed. In total, 284 chronic Q fever patients were identified, of which 151 (53.7%) had proven, 64 (22.5%) probable, and 69 (24.3%) possible chronic Q fever. Among proven and probable chronic Q fever patients, vascular infection focus (56.7%) was more prevalent than endocarditis (34.9%). An acute Q fever episode was recalled by 27.0% of the patients. The all-cause mortality rate was 19.1%, while the chronic Q fever-related mortality rate was 13.0%, with mortality rates of 9.3% among endocarditis patients and 18% among patients with a vascular focus of infection. Increasing age (P = 0.004 and 0.010), proven chronic Q fever (P = 0.020 and 0.002), vascular chronic Q fever (P = 0.024 and 0.005), acute presentation with chronic Q fever (P = 0.002 and P < 0.001), and surgical treatment of chronic Q fever (P = 0.025 and P < 0.001) were significantly associated with all-cause mortality and chronic Q fever-related mortality, respectively.


BMC Infectious Diseases | 2013

Localizing chronic Q fever: a challenging query

Dennis G. Barten; Corine E. Delsing; Stephan P. Keijmel; Tom Sprong; Janneke Timmermans; Wim J.G. Oyen; Marrigje H. Nabuurs-Franssen; Chantal P. Bleeker-Rovers

BackgroundChronic Q fever usually presents as endocarditis or endovascular infection. We investigated whether 18F-FDG PET/CT and echocardiography were able to detect the localization of infection. Also, the utility of the modified Duke criteria was assessed.MethodsFifty-two patients, who had an IgG titre of ≥ 1024 against C. burnetii phase I ≥ 3 months after primary infection or a positive PCR ≥ 1 month after primary infection, were retrospectively included. Data on serology, the results of all imaging studies, possible risk factors for developing proven chronic Q fever and clinical outcome were recorded.ResultsAccording to the Dutch consensus on Q fever diagnostics, 18 patients had proven chronic Q fever, 14 probable chronic Q fever, and 20 possible chronic Q fever. Of the patients with proven chronic Q fever, 22% were diagnosed with endocarditis, 17% with an infected vascular prosthesis, and 39% with a mycotic aneurysm. 56% of patients with proven chronic Q fever did not recall an episode of acute Q fever. Ten out of 13 18F-FDG PET/CT-scans in patients with proven chronic Q fever localized the infection. TTE and TEE were helpful in only 6% and 50% of patients, respectively.ConclusionsIf chronic Q fever is diagnosed, 18F-FDG PET/CT is a helpful imaging technique for localization of vascular infections due to chronic Q fever. Patients with proven chronic Q fever were diagnosed significantly more often with mycotic aneurysms than in previous case series. Definite endocarditis due to chronic Q fever was less frequently diagnosed in the current study. Chronic Q fever often occurs in patients without a known episode of acute Q fever, so clinical suspicion should remain high, especially in endemic regions.


Clinical Infectious Diseases | 2018

Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV Therapy

Anne Boerekamps; Guido E.L. van den Berk; Lauw N Fanny; Eliane M. S. Leyten; Marjo van Kasteren; Arne van Eeden; D. Posthouwer; Mark A.A. Claassen; Anton S Dofferhoff; Dominique W M Verhagen; Wouter F. W. Bierman; Kamilla D. Lettinga; Frank P. Kroon; Corine E. Delsing; Paul H. P. Groeneveld; Robert Soetekouw; Edgar J.G. Peters; Sebastiaan J. Hullegie; Stephanie Popping; David A. M. C. van de Vijver; Charles A. Boucher; Joop E. Arends; Bart J. A. Rijnders

Background Direct-acting antivirals (DAAa) cure hepatitis C virus (HCV) infections in 95% of infected patients. Modeling studies predict that universal HCV treatment will lead to a decrease in the incidence of new infections but real-life data are lacking. The incidence of HCV among Dutch human immunodeficiency virus (HIV)-positive men who have sex with men (MSM) has been high for >10 years. In 2015 DAAs became available to all Dutch HCV patients and resulted in a rapid treatment uptake in HIV-positive MSM. We assessed whether this uptake was followed by a decrease in the incidence of HCV infections. Methods Two prospective studies of treatment for acute HCV infection enrolled patients in 17 Dutch HIV centers, having 76% of the total HIV-positive MSM population in care in the Netherlands. Patients were recruited in 2014 and 2016, the years before and after unrestricted DAA availability. We compared the HCV incidence in both years. Results The incidence of acute HCV infection decreased from 93 infections during 8290 person-years of follow-up (PYFU) in 2014 (11.2/1000 PYFU; 95% confidence interval [CI], 9.1-13.7) to 49 during 8961 PYFU in 2016 (5.5/1000 PYFU; 4.1-7.2). The incidence rate ratio of 2016 compared with 2014 was 0.49 (95% CI, .35-.69). Simultaneously, a significant increase in the percentage positive syphilis (+2.2%) and gonorrhea (+2.8%) tests in HIV-positive MSM was observed at sexual health clinics across the Netherlands and contradicts a decrease in risk behavior as an alternative explanation. Conclusions Unrestricted DAA availability in the Netherlands was followed by a 51% decrease in acute HCV infections among HIV-positive MSM.


Advances in Experimental Medicine and Biology | 2012

Q Fever: still more queries than answers

Corine E. Delsing; Adilia Warris; Chantal P. Bleeker-Rovers

Q fever is a worldwide zoonosis, caused by C. burnetii. Infection usually occurs through inhalation of infected aerosols. The reservoir mainly consists of dairy cattle. Clinical symptoms of acute Q fever are non-specific and resemble a mild flu-like illness. Children often present with gastrointestinal symptoms and rash. Rarely, chronic infection develops. This is usually manifested as endo-carditis, vascular infection and, in children, osteomyelitis. Diagnosis is based on serology and nucleic acid amplification (PCR). Doxycycline is the treatment of choice for acute infection. An alternative for young children and pregnant women is cotrimoxazole. Chronic infection requires long term treatment usually with doxycycline combined with hydroxychloroquine.


Emerging Infectious Diseases | 2015

Chronic Q Fever Diagnosis— Consensus Guideline versus Expert Opinion.

Linda M. Kampschreur; M. C. A. Wegdam-Blans; Peter C. Wever; Nicole H. M. Renders; Corine E. Delsing; Tom Sprong; M.E. van Kasteren; Henk A. Bijlmer; D.W. Notermans; Jan Jelrik Oosterheert; F.S. Stals; Marrigje H. Nabuurs-Franssen; Chantal P. Bleeker-Rovers

Literature-based consensus guideline is more sensitive and easier to use in clinical practice.


BMC Infectious Diseases | 2013

The Qure study: Q fever fatigue syndrome – response to treatment; a randomized placebo-controlled trial

Stephan P. Keijmel; Corine E. Delsing; Tom Sprong; Gijs Bleijenberg; Jos W. M. van der Meer; Hans Knoop; Chantal P. Bleeker-Rovers

BackgroundQ fever is a zoonosis that is present in many countries. Q fever fatigue syndrome (QFS) is one of the most frequent sequelae after an acute Q fever infection. QFS is characterized by persistent fatigue following an acute Q fever infection, leading to substantial morbidity and a high socio-economic burden. The occurrence of QFS is well-documented, and has been described in many countries over the past decades. However, a treatment with proven efficacy is not available. Only a few uncontrolled studies have tested the efficacy of treatment with antibiotics on QFS. These studies suggest a positive effect of long-term treatment with a tetracycline on performance state; however, no randomized controlled trials have been performed. Cognitive behavioral therapy (CBT) has been proven to be an effective treatment modality for chronic fatigue in other diseases, but has not yet been tested in QFS. Therefore, we designed a trial to assess the efficacy of long-term treatment with the tetracycline doxycycline and CBT in patients with QFS.Methods/designA randomized placebo-controlled trial will be conducted. One-hundred-eighty adult patients diagnosed with QFS will be recruited and randomized between one of three groups: CBT, long-term doxycycline or placebo. First, participants will be randomized between CBT and medication (ratio 1:2). A second double-blinded randomization between doxycycline and placebo (ratio 1:1) will be performed in the medication condition. Each group will be treated for six months. Outcome measures will be assessed at baseline and post intervention. The primary outcome measure is fatigue severity. Secondary outcome measures are functional impairment, level of psychological distress, and Coxiella burnetii PCR and serology.DiscussionThe Qure study is the first randomized placebo-controlled trial, which evaluates the efficacy of long-term doxycycline and of cognitive behavioral therapy in patients with QFS. The results of this study will provide knowledge about evidence-based treatment options for adult patients with QFS.Trial registrationClinicalTrials.gov: http://NCT01318356, and Netherlands Trial Register: NTR2797


Emerging Infectious Diseases | 2015

Differentiation of Acute Q Fever from Other Infections in Patients Presenting to Hospitals, the Netherlands(1)

Stephan P. Keijmel; Elmer Krijger; Corine E. Delsing; Tom Sprong; Marrigje H. Nabuurs-Franssen; Chantal P. Bleeker-Rovers

Distinguishing acute Q fever from respiratory infections, fever, or hepatitis requires serologic testing or PCR.


Clinical Infectious Diseases | 2017

Effectiveness of Long-term Doxycycline Treatment and Cognitive-Behavioral Therapy on Fatigue Severity in Patients with Q Fever Fatigue Syndrome (Qure Study): A Randomized Controlled Trial

Stephan P. Keijmel; Corine E. Delsing; Gijs Bleijenberg; Jos W. M. van der Meer; Rogier Donders; Monique Leclercq; Linda M. Kampschreur; Michel van den Berg; Tom Sprong; Marrigje H. Nabuurs-Franssen; Hans Knoop; Chantal P. Bleeker-Rovers

Background Approximately 20% of patients with acute Q fever will develop chronic fatigue, referred to as Q fever fatigue syndrome (QFS). The objective of this randomized controlled clinical trial was to assess the efficacy of either long-term treatment with doxycycline or cognitive-behavioral therapy (CBT) in reducing fatigue severity in patients with QFS. Methods Adult patients were included who met the QFS criteria according to the Dutch guideline: a new onset of severe fatigue lasting ≥6 months with significant disabilities, related to an acute Q fever infection, without other somatic or psychiatric comorbidity explaining the fatigue. Using block randomization, patients were randomized between oral study medication and CBT (2:1) for 24 weeks. Second, a double-blind randomization between doxycycline (200 mg/day, once daily) and placebo was performed in the medication group. Primary outcome was fatigue severity at end of treatment (EOT; week 26), assessed with the Checklist Individual Strength subscale Fatigue Severity. Results Of 155 patients randomized, 154 were included in the intention-to-treat analysis (doxycycline, 52; placebo, 52; CBT, 50). At EOT, fatigue severity was similar between doxycycline (40.8 [95% confidence interval {CI}, 37.3-44.3]) and placebo (37.8 [95% CI, 34.3-41.2]; difference, doxycycline vs placebo, -3.0 [97.5% CI, -8.7 to 2.6]; P = .45). Fatigue severity was significantly lower after CBT (31.6 [95% CI, 28.0-35.1]) than after placebo (difference, CBT vs placebo, 6.2 [97.5% CI, .5-11.9]; P = .03). Conclusions CBT is effective in reducing fatigue severity in QFS patients. Long-term treatment with doxycycline does not reduce fatigue severity in QFS patients compared to placebo. Clinical Trials Registration NCT01318356.


PLOS ONE | 2016

Fatigue following Acute Q-Fever: A Systematic Literature Review

Gabriëlla Morroy; Stephan P. Keijmel; Corine E. Delsing; Gijs Bleijenberg; Miranda W. Langendam; Aura Timen; Chantal P. Bleeker-Rovers

Background Long-term fatigue with detrimental effects on daily functioning often occurs following acute Q-fever. Following the 2007–2010 Q-fever outbreak in the Netherlands with over 4000 notified cases, the emphasis on long-term consequences of Q-fever increased. The aim of this study was to provide an overview of all relevant available literature, and to identify knowledge gaps regarding the definition, diagnosis, background, description, aetiology, prevention, therapy, and prognosis, of fatigue following acute Q-fever. Design A systematic review was conducted through searching Pubmed, Embase, and PsycInfo for relevant literature up to 26th May 2015. References of included articles were hand searched for additional documents, and included articles were quality assessed. Results Fifty-seven articles were included and four documents classified as grey literature. The quality of most studies was low. The studies suggest that although most patients recover from fatigue within 6–12 months after acute Q-fever, approximately 20% remain chronically fatigued. Several names are used indicating fatigue following acute Q-fever, of which Q-fever fatigue syndrome (QFS) is most customary. Although QFS is described to occur frequently in many countries, a uniform definition is lacking. The studies report major health and work-related consequences, and is frequently accompanied by nonspecific complaints. There is no consensus with regard to aetiology, prevention, treatment, and prognosis. Conclusions Long-term fatigue following acute Q-fever, generally referred to as QFS, has major health-related consequences. However, information on aetiology, prevention, treatment, and prognosis of QFS is underrepresented in the international literature. In order to facilitate comparison of findings, and as platform for future studies, a uniform definition and diagnostic work-up and uniform measurement tools for QFS are proposed.

Collaboration


Dive into the Corine E. Delsing's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tom Sprong

Radboud University Nijmegen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Stephan P. Keijmel

Radboud University Nijmegen

View shared research outputs
Top Co-Authors

Avatar

Gijs Bleijenberg

Radboud University Nijmegen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gabriëlla Morroy

Radboud University Nijmegen Medical Centre

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge